Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -35.83% is 75% above its 5-year average of -142.41%, near the high end of its 5-year range (-402.44%–-19.17%).
0.42% above its 12-month average of -35.98%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -28.98%.
EBITDA MARGIN
-35.83%
EBITDA MARGIN AVG TTM
-35.98%
EBITDA MARGIN AVG 3Y
-47.23%
EBITDA MARGIN AVG 5Y
-142.41%
EBITDA MARGIN AVG 10Y
-1016.08%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.42%
CURRENT VS 3Y AVG
+24.13%
CURRENT VS 5Y AVG
+74.84%
CURRENT VS 10Y AVG
+96.47%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
electroCore, Inc.
Market Cap
$91.33M
EBITDA Margin
-35.83%
TTM Avg
-35.98%
3Y Avg
-47.23%
5Y Avg
-142.41%
Market Cap
$91.68M
EBITDA Margin
-19.79%
TTM Avg
-29.84%
3Y Avg
-150.95%
5Y Avg
-150.95%
Market Cap
$88.21M
EBITDA Margin
15.84%
TTM Avg
9.89%
3Y Avg
0.86%
5Y Avg
4.00%
Market Cap
$87.86M
EBITDA Margin
-8103.88%
TTM Avg
-7583.93%
3Y Avg
-8667.05%
5Y Avg
-7944.60%
Market Cap
$84.75M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$84.70M
EBITDA Margin
31.45%
TTM Avg
-14.67%
3Y Avg
-906.21%
5Y Avg
-1050.55%
Market Cap
$84.00M
EBITDA Margin
-4911.29%
TTM Avg
-4911.29%
3Y Avg
-4895.51%
5Y Avg
-4835.22%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| electroCore, Inc. (ECOR) | $91.33M | -35.83% | -35.98% | -47.23% | -142.41% |
| Equillium, Inc. (EQ)vs › | $91.68M | -19.79% | -29.84% | -150.95% | -150.95% |
| Biomea Fusion, Inc. (BMEA)vs › | $93.99M | N/A | N/A | N/A | N/A |
| ImmuCell Corporation (ICCC)vs › | $88.21M | 15.84% | 9.89% | 0.86% | 4.00% |
| Cardiff Oncology, Inc. (CRDF)vs › | $87.86M | -8103.88% | -7583.93% | -8667.05% | -7944.60% |
| CareCloud, Inc. (CCLD)vs › | $86.69M | 23.63% | 23.21% | 8.97% | 9.09% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $84.75M | N/A | N/A | N/A | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.70M | 31.45% | -14.67% | -906.21% | -1050.55% |
| Humacyte, Inc. (HUMA)vs › | $84.00M | -4911.29% | -4911.29% | -4895.51% | -4835.22% |
| Cognition Therapeutics, Inc. (CGTX)vs › | $83.96M | N/A | N/A | N/A | N/A |
Gross Margin
87.1%
EBITDA Margin
-35.8%
Operating Margin
-37.6%
Net Margin
-40.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -28.98% |
| 2026-03-31 | -54.98% |
| 2025-12-31 | -19.17% |
| 2025-09-30 | -31.43% |
| 2025-06-30 | -45.35% |
| 2025-03-31 | -54.00% |
| 2024-12-31 | -35.35% |
| 2024-09-30 | -36.97% |
| 2024-06-30 | -38.51% |
| 2024-03-31 | -66.62% |
| 2023-12-31 | -70.66% |
| 2023-09-30 | -84.72% |
| 2023-06-30 | -130.98% |
| 2023-03-31 | -217.99% |
| 2022-12-31 | -225.35% |
| 2022-09-30 | -273.43% |
| 2022-06-30 | -263.28% |
| 2022-03-31 | -288.31% |
| 2021-12-31 | -360.66% |
| 2021-09-30 | -261.53% |
| 2021-06-30 | -402.44% |
| 2021-03-31 | -439.20% |
| 2020-12-31 | -669.27% |
| 2020-09-30 | -406.51% |
| 2020-06-30 | -773.91% |
| 2020-03-31 | -1078.78% |
| 2019-12-31 | -1260.56% |
| 2019-09-30 | -1580.57% |
| 2019-06-30 | -1983.57% |
| 2019-03-31 | -3463.25% |
| 2018-12-31 | -4259.42% |
| 2018-09-30 | -8962.73% |
| 2018-06-30 | -4123.96% |
| 2018-03-31 | -11198.47% |
| 2017-12-31 | -3184.13% |
| 2017-09-30 | -2111.30% |
| 2017-06-30 | -4204.44% |
| 2017-03-31 | -4049.33% |
